JBIO
Jade Biosciences, Inc.
Healthcare — Biotechnology
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Strong Buy
1.0 / 5
8 analysts
$13.77
$-0.28 (-1.99%)
Target:
$48.50
(252.2%)
Price History
52-Week Range
Sign in to add JBIO to a watchlist or set price alerts.
Fundamentals
| Market Cap | $1.33B |
| P/E Ratio (TTM) | - |
| Forward P/E | -9.57 |
| EPS (TTM) | $-2.63 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 0.27 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $48.50 |
| Analysts | 8 |
| Next Earnings | Aug 10, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 81.5 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $28.00 |
| 52-Week Low | $6.67 |
| 50-Day Avg | $21.45 |
| 200-Day Avg | $15.21 |
| Avg Volume | 989.2K |
| Volume | 774.4K |
Performance Analysis
NEUTRALJBIO presents a mixed picture with both positive and negative indicators.
~
Trading at 33% of its 52-week range.
-
RSI at 81.5 indicates overbought conditions — a pullback may be due.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Wall Street consensus is "Strong Buy" from 8 analysts.
+
Average analyst target of $48.50 implies 252.2% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:16 UTC
Back to Screener Export Report